DiaMedica TherapeuticsNASDAQ: DMAC

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. The transaction is expected to result in gross proceeds of $11.8 million. A placement agent was not used in connection with this private placement. Pursuant to the terms of t.

DiaMedica (DMAC) shares increase by 10% after the company administers the initial dose to the first patient in the restart of its crucial trial assessing the primary candidate, DM199, for the treatment of acute ischemic stroke.

DiaMedica Therapeutics (DMAC) is currently in oversold territory, indicating that the intense selling pressure may have subsided. Coupled with widespread consensus among Wall Street analysts in increasing earnings projections, this could result in a potential turnaround for the stock.

DiaMedica Therapeutics (NASDAQ: DMAC ) just reported results for the fourth quarter of 2023. DiaMedica Therapeutics reported earnings per share of -14 cents.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alexander Nowak - Craig-Hallum Capital Group Francois Brisebois - Oppenheimer. Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call.

Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Capital Group Dan Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Second Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its second quarter 2023 financial results will be released after the markets close on Monday, August 14th. DiaMedica will host a live conference call on Tuesday, August 15th at 7:00 AM Central Time to provide a business update and discuss financial results. Co.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Alex Nowak - Craig-Hallum Daniel Hultberg - Oppenheimer Operator Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica's website at www.diamedica.com in the Investor Relations section.